GlassScriptPhysician profile
Michael Tomczyk
NPI 1871244723
$4,906.30
in general payments reported to CMS, 2019-2025
21 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,369 · 2023: $2,002 · 2024: $323 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,537.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,147.76 | 2022-2025 | Watchman Flx, Watchman Access System, Watchman |
| Astrazeneca Pharmaceuticals LP | $418.24 | 2022-2025 | Farxiga, Brilinta, Lokelma |
| Novo Nordisk INC | $400.01 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.62 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $355.24 | 2022-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $347.86 | 2022-2023 | Xarelto |
| Pfizer INC. | $272.37 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $231.52 | 2022-2023 | Amvuttra, Onpattro |
| Amgen INC. | $228.51 | 2022-2025 | Repatha, Repatha |
| Biotronik INC. | $187.07 | 2022 | |
| Novartis Pharmaceuticals Corporation | $186.61 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $155.90 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $146.58 | 2022-2023 | |
| Impulse Dynamics (USA) INC. | $120.98 | 2022 | |
| Lantheus Medical Imaging, INC. | $117.50 | 2023 | Definity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $90.67 | 2022-2023 | Verquvo |
| Cvrx, INC. | $28.24 | 2023 | Barostim Neo System |
| Abbott Laboratories | $24.00 | 2023 | Cardiomems |
| Azurity Pharmaceuticals, INC. | $21.05 | 2023 | Edarbyclor |
| Kiniksa Pharmaceuticals, LTD. | $18.52 | 2023 | Arcalyst |
| Scpharmaceuticals INC. | $16.05 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tomczyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.